<DOC>
	<DOCNO>NCT02378389</DOCNO>
	<brief_summary>Pyrotinib oral tyrosine kinase inhibitor target EGFR HER-2 receptor . This study design evaluate safety tolerability Pyrotinib Pyrotinib combination Docetaxel patient HER2 positive advance gastric cancer .</brief_summary>
	<brief_title>Study Evaluating Pyrotinib/Pyrotinib Combination With Docetaxel Patients With HER2+ Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Aged ≥18 ≤70 year . ECOG performance status 0 1 . Life expectancy 12 week . At least one measurable lesion exists . ( RECIST 1.1 ) . Histologically cytologic confirm HER2 positive advance gastric cancer ( include adenocarcinoma esophagealgastric junction ) , clinical phase III/IV . No severe impairment liver kidney function , require laboratory value include follow parameter : ANC : ≥1.5x109/L , Platelet count : ≥90x109/L , Hemoglobin : ≥9.0 g/dL , Total bilirubin : ≤1xULN , ALT AST : ≤1.5xULN ( patient liver metastasis , ALT AST : ≤5xULN ) , ALP : ≤2.5xULN , BUN creatine : ≤1xULN , creatine clearance rate : ≥50 mL/min , LVEF : ≥50 % , QTcF : &lt; 450 m ( male ) , &lt; 470 m ( female ) , INR : ≤1.5xULN , APTT : ≤1.5xULN . Signed informed consent . For subject treat Pyrotinib : Failed intolerable prior therapy . For subject treat Pyrotinib Docetaxel : Failed intolerable prior therapy , previous treatment taxane , previous treatment HER2 target inhibitor . Subjects third space fluid control drainage method . Subjects unable swallow tablet , dysfunction gastrointestinal absorption . Steroid treatment 50 day , need longterm use steroid . Less 4 week last radiotherapy , chemotherapy，surgery，hermone treatment , target therapy , less 6 week nitrosoureas mitomycin chemotherapy . Less 4 week last clinical trial adverse event previous trial ( include alopecia asthenia ) . Subjects uncontrolled hypokalemia hypomagnesemia study entry . Subjects interrupt use drug cause QT prolongation study . Subjects intracranial lesion ( MRI CT ) . Subjects suffer malignancy last 5 year , include cervical carcinoma situ , basal cell carcinoma squamous cell carcinoma . Subjects bone skin target lesion . Receiving antitumor therapy . Known history hypersensitivity component metabolites investigational drug Tween80 . Subjects clear tendency gastointestinal bleeding . Including follow : subject local active ulcer lesion fecal occult blood ( ++ ) exclude ; subject le 2 month last history black stools haematemesis exclude ; subject fecal occult blood ( + ) primary lesion resect , endoscopy require , gastric ulcer find principal investigator site consider possible occurence gastointestinal bleeding , subject exclude . Ongoing infection peripheral neuropathy ( determined investigator ) . History immunodeficiency , include HIVpositive , suffer acquire , congenital immunodeficiency disease , history organ transplantation . Subjects heart disease , include : ( 1 ) angina ; ( 2 ) require medication clinically significant arrhythmia ; ( 3 ) myocardial infarction ; ( 4 ) heart failure ; ( 5 ) Any heart disease judge investigator unsuitable participate trial . Female patient pregnancy , lactation woman childbearing potential test positive baseline pregnancy test reluctant take effective contraceptive measure throughout trial period . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study . Examples include , limited , hypertension , severe diabetes , thyroid disease . Alcoholism , smoking ( daily ≥ 5 root ) bad habit . Known history neurological psychiatric disease , include epilepsy dementia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>